Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)

The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.

NCT Number	NCT06889818
Lead Sponsor	Ewha Womans University Mokdong Hospital Collaborators: Korean Dementia Association, Inha University Hospital, Gachon University Gil Medical Center, Saint Vincent's Hospital, Korea, Gangnam Severance Hospital, Konkuk University Hospital, Kyunghee University Medical Center, Korea University Medicine, Busan University Medical Center, CHA University, Samsung Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital, Asan Medical Center, Soonchunhyang University Hospital, Ajou University School of Medicine, Yonsei University Yongin Severance Hospital, Wonkwang University Hospital, Ewha Womans University Seoul Hospital, InjeUniversityBusanPaikHospital, Chonnam National University Hospital, Jeju National University Hospital, Chungnam National University Hospital, Gyungbook national university hospital, Hanllym University Medical Center, Heavenly Clinical Research, KangWon National University Hospital, Seoul St. Mary's Hospital
Conditions	Mild Cognitive Impairment, Dementia, Subjective Cognitive Decline (SCD), Alzheimer Disease
Enrollment	4,000 participants
Start Date	2025-02-24
Primary Completion	2034-12-31 (estimated)
Study Completion	2034-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-21